- The paper linked is not a study --
it is an aggregation of existing articles. See the
Methods section on page 1: "
We performed a systematic review of the PubMed and EMBASE databases from inception to 1 March 2020 to find articles providing information on the efficacy and safety of chloroquine and chloroquine-related formulations in patients with SARS-CoV-2 pneumonia and articles describing related in-vitro studies."
- In their
Results section (
my capital lettering) : "
[We] found six relevant articles (A. one narrative letter, B. one research letter, C. one editorial, D. one expert consensus paper in Chinese, E. one national guideline document in Dutch and one in Italian). F. Twenty-three trials were found in the trial registries."
In order:
-
A. From their
Discussion section, pg 3: "
A narrative letter by Chinese authors reported that a news briefing from the State Council of China had indicated that 'Chloroquine phosphate...had demonstrated marked efficacy and acceptable safety in treating COVID-19 associated pneumonia in multicentre clinical trials conducted in China' [5]. The authors also stated that these findings came from 'more than 100 patients' included in the trials [5]. We sought for evidence of such data in the trial registries we reviewed and found none."
The authors are too kind. I inserted the links to the cited article (the [5]s) -- please click on them and note that the reference is to an abstract and references, void of any actual experiment whatsoever. Not much better than a "Terms of Service" dead link.
-
B. From their
Discussion section, pg 3:
"The research letter, written by a group of Chinese researchers, studied the effect of chloroquine in vitro, using Vero E6 cells infected by SARS-CoV-2 at a multiplicity of infection (MOI) of 0.05. The study demonstrated that chloroquine was highly effective in reducing viral replication, with an Effective Concentration (EC)90of 6.90μM that can be easily achievable with standard dosing, due to its favourable penetration in tissues, including in the lung. ... The authors also speculated on the possibility that the known immunomodulant effect of the drug may enhance the antiviral effect in vivo."
-
C. From their
Discussion section, pg 3: "
The Editorial written by French researchers, underlined the in-vitro efficacy of chloroquine in other viral infections, especially SARS (whose disappearance resulted in limited further research). They also discussed the potentially favourable risk-benefit balance, the high safety, and the low expenditure of such treatment in the context of the current COVID-19 outbreak."
One of the authors of this editorial, Dr. Didier Raoult, has been mentioned and discussed in this thread. He is a legitimate and noted researcher in the field of infectious diseases. Subsequent to this editorial, he was part of a team that conducted a limited trial (>30 patients) of
a therapy combining hydroxychloroquine and the popular antibiotic azithromycin.
While initially being touted as a promising set of results, Raoult's methods in achieving
those results proved questionable under further scrutiny (
The Intercept, 3/24/2020):
-
D. From their
Discussion section, pg 3-4: "
The expert consensus was published on 20th February by a multicentre collaboration group of the Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province paper and related specifically to the use of chloroquinephosphate [7] (NOTE: Dead Google Scholar link - DB). No information was provided on the method used to achieve consensus [7]. Based on in vitro evidence and still unpublished clinical experience, the panel recommended chloroquine phosphate tablet, at a dose of 500 mg twice per day for 10 days, for patients diagnosed as mild, moderate and severe cases ..."
Chloroquine phosphate, meant for parasite control in fish tanks, is
what killed a man in Arizona this past weekend (NBC News, 3/23/2020).
-
E. From their
Discussion section, pg 4: "
The Dutch Center of Disease control (CDC), in a public document on its website (NOTE: not anymore - DB), suggested to treat severe infections requiring admission to the hospital and oxygen therapy or admitted to the ICU with chloroquine, [8] (NOTE: another dead link - DB). However, the document also stated that treating patients only with optimal supportive care is still a reasonable option, due to lack of supportive evidence."
"Another guideline document by the Italian Society of Infectious and Tropical disease (Lombardy section) recommend the use of chlorochine 500 mg × 2/die or hydroxychloroquine 200 mg die for 10 days, although the treatment may vary from 5 to 20 days according to clinical severity. The suggested target population ranged from patients with mild respiratory symptoms and comorbidities to patients with severe respiratory failure [
9]."
(NOTE: yep -- yet another dead link - DB)
-
F. The chart about the incipient trials is interesting, but note that everything they cited is from March 1st and earlier (see
Methods, pg 1). See the second column in the trials chart (
pgs 2-3 here) titled 'Recruiting Status'. That column shows that not a one of those 23 trials had even begun -- all statuses shown were either 'Pre-approval', 'Not yet recruiting' or 'Recruiting'. None of the 23 were underway as of 3/1.